Association analysis between ICI efficacy data and multi-omics data (2) (IMAGE)
Caption
(A) Scatter plot demonstrating the association between the gene expression levels of the AATF and mOS data of cancer patients treated with ICIs. (B) Scatter plot showing the association between the mutation rate of the BER pathway and mOS data of cancer patients treated with ICIs. (C) Scatter plot showing the association between the mutation rate of the the Notch signaling pathway and the mOS data of cancer patients treated with ICIs. (D) Scatter plot showing the association between the expression level of the mTORC1 signaling pathway and the mOS data of cancer patients treated with ICIs. The aforementioned tumor transcriptome data were sourced from the TCGA database, gene mutation data were obtained from the cBioPortal database, and tumor pathway-associated gene sets were downloaded from the MSigDB. The r and p values were calculated through Pearson and Spearman association analyses, respectively. Abbreviations: ICIs, immune checkpoint inhibitors; mOS, median overall survival; HROS, hazard ratios for overall survival; BER, base excision repair; BLCA, bladder urothelial carcinoma; BRCA, breast invasive carcinoma; COAD, colon adenocarcinoma; ESCA, esophageal carcinoma; HNSC, head and neck squamous cell carcinoma; KIRC, kidney renal clear cell carcinoma; LIHC, liver hepatocellular carcinoma; LUAD, lung adenocarcinoma; LUSC, lung squamous cell carcinoma; PRAD, prostate adenocarcinoma; SKCM, skin cutaneous melanoma; STAD, stomach adenocarcinoma.
Credit
Dr. Peng Luo
Usage Restrictions
Marked by the credited
License
Original content